{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019991", "CSN": null, "TRF": "ORD_1341410_01", "MRN": "41115246", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1098826", "clinicalId": "1100197", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1341410_01", "SampleName": "US1289010.01", "Version": "0", "Sample": {"FM_Id": "ORD_1341410_01", "SampleId": "US1289010.01", "BlockId": "S111-12810A", "TRFNumber": "ORD_1341410_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_04_12", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-99078", "MRN": "41115246", "FullName": "\u9ad8\u5ba3\u96ef", "FirstName": "Hsuan_Wen", "LastName": "Huang", "SubmittedDiagnosis": "Anaplastic astrocytoma, Cerebrum", "Gender": "Female", "DOB": "1993_10_30", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_03_28", "ReceivedDate": "2022-04-21 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "16", "clinicalTrialCount": "11", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "FGFR3", "isVUS": "true", "variantName": "D580N"}, {"geneName": "MLH1", "isVUS": "true", "variantName": "R217C"}, {"geneName": "MTOR", "isVUS": "true", "variantName": "H1744Y"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "E739K"}, {"geneName": "NTRK1", "isVUS": "true", "variantName": "R220Q"}, {"geneName": "PDGFRA", "isVUS": "true", "variantName": "L112F"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "T796S"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "FGFR1", "Include": "true", "Alterations": {"Alteration": {"Name": "N546K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "N546K"}}, "Interpretation": "FGFR1 encodes the protein fibroblast growth factor receptor 1, which plays key roles in regulation of the cell cycle and angiogenesis and is an upstream regulator of the RAS, MAPK, and AKT signaling pathways (Turner and Grose, 2010; 20094046). The FGFR1 alteration observed here has been characterized as activating and is predicted to be oncogenic (Lew et al., 2009; 19224897, Liu et al., 2003; 14602678, Petiot et al., 2002; 12112473, Hart et al., 2000; 10918587). In the Brain Lower Grade Glioma TCGA dataset and the Glioblastoma Multiforme TCGA dataset, mutation of FGFR1 has been found in less than 1% of cases (cBio_Brennan et al., 2013; 24120142, Cancer Genome Atlas Research Network., 2015; 26061751). In pediatric patients, FGFR1 alterations have been identified in 18% of low_grade gliomas (Johnson et al., 2017; 28912153), including 5/9 pilomyxoid astrocytomas, 8% of high_grade gliomas (Johnson et al., 2017; 28912153), and in 6% (4/64) of thalamic gliomas (Ryall et al., 2016; 27577993). FGFR1 mutation has also been reported in 5% (5/96) of pilocytic astrocytomas (Jones et al., 2013; 23817572). Mutations in the FGFR1 kinase domain have been reported in both lower_grade gliomas and glioblastomas; one of these mutations has been described as an oncogenic mutation that disrupted autophosphorylation (Rand et al., 2005; 16186508, Lew et al., 2009; 19224897, Zhang et al., 2013; 23583981). FGFR fusions were identified in 3/85 IDH1 and IDH2 wild_type gliomas, but were not found in any of 126 IDH1_ or IDH2_mutant gliomas (Di Stefano et al., 2015; 25609060). Patients with FGFR1_altered pilocytic astrocytomas have been associated with poor prognosis (Becker et al., 2015; 26083571, Ahrendsen et al., 2021; 34580728), although published data investigating the prognostic implications of FGFR1 alterations independent to co_occurring alterations in gliomas are limited (PubMed, Mar 2022) (Ryall et al., 2016; 27577993, Schuller et al., 2021; 33433639). Alterations that activate FGFR1 may predict sensitivity to selective FGFR inhibitors including erdafitinib (Loriot et al., 2019; 31340094, Tabernero et al., 2015; 26324363, Karkera et al., 2017; 28416604, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Necchi et al., 2018; ESMO Abstract 900P), infigratinib (Pal et al., 2018; 29848605, Pal et al., 2020; 32208524), rogaratinib (Schuler et al., 2019; 31405822), Debio 1347 (Sait et al., 2021; 34250399, Voss et al., 2019; 30745300), futibatinib (Bahleda et al., 2020; 32622884), and derazantinib (Papadopoulos et al., 2017; 28972963), or multikinase inhibitors such as pazopanib (Cheng et al., 2017; 29223982, Yuan et al., 2016; SABCS Abstract P6_16_08) and ponatinib (Khodaoust et al., 2015; 26055304, Tanasi et al., 2019; 31434701, Strati et al., 2018; 29119847, Kreil et al., 2015; Abstract 2812). In the context of FGFR1 mutation, clinical responses have been reported in patients with primary brain tumors (Bahleda et al., 2020; 32622884, Lassman et al., 2019; SNO Abstract ACTR_33, Sait et al., 2021; 34250399) and lung squamous cell carcinoma (Slosberg et al., 2018; 29765547) treated with FGFR inhibitors. In a phase 1 study of futibatinib, 2 patients with FGFR1_mutated primary brain tumors exhibited PRs (Bahleda et al., 2020; 32622884). A patient with FGFR1_mutated glioblastoma exhibited a PR when treated with infigratinib (Lassman et al., 2019; SNO Abstract ACTR_33). For pediatric patients with FGFR1_mutated gliomas, a case series reported 1 sustained PR for a patient with high grade glioma, and a sustained SD and 1 PD for patients with low grade gliomas following treatment with Debio 1347 (Sait et al., 2021; 34250399). In pediatric gliomas lacking typical BRAF and NF1 driver alterations, RAS/MAPK hyperactivation arising from non_KIAA1549 fusions with BRAF, non_V600 BRAF mutations, FGFR1/2 fusions, FGFR1 mutations, RAF1 fusions, KRAS mutations, or MYB or MYBL1 rearrangements are typical of the WHO entity diffuse low_grade glioma, MAPK pathway_altered (Pfister et al., 2022; 34921008, Ryall et al., 2020; 32289278, Cheng et al., 2021; ASCO Abstract e14022, Qaddoumi et al., 2016; 26810070, Zhang et al., 2013; 23583981).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Infigratinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Infigratinib is a TKI that inhibits FGFR1, FGFR2, and FGFR3. It is FDA approved for the treatment of patients with unresectable locally advanced or metastatic cholangiocarcinoma who have FGFR2 rearrangements or fusions and have progressed after prior therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Based on individual responses in patients with FGFR1_mutated glioblastoma (Lassman et al., 2019; SNO Abstract ACTR_33) and lung squamous cell carcinoma (Slosberg et al., 2018; 29765547), FGFR1 mutation may predict sensitivity to infigratinib. </p> <p><b>Supporting Data:</b> A Phase 2 study of infigratinib for patients with recurrent high_grade gliomas harboring FGFR alterations, reported a 9.5% (2/21) ORR, 1.7 month median PFS, and 6.7 month median OS (Lassman et al., 2019; SNO Abstract ACTR_33). Disease control greater than one year was observed in 4 patients, including a PR in a patient with FGFR1_mutated glioma, and SD in patients with glioma harboring FGFR1 mutation, FGFR3 mutation, or FGFR3_TACC3 fusion (Lassman et al., 2019; SNO Abstract ACTR_33). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04169672", "Include": "true"}, {"nctId": "NCT04977453", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT04962867", "Include": "true"}, {"nctId": "NCT03564691", "Include": "true"}, {"nctId": "NCT03547037", "Include": "true"}, {"nctId": "NCT04008797", "Include": "true"}, {"nctId": "NCT04424966", "Include": "true"}, {"nctId": "NCT04565275", "Include": "true"}, {"nctId": "NCT02549937", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "H3F3A", "Include": "true", "Alterations": {"Alteration": {"Name": "K28M", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "K28M"}}, "Interpretation": "H3F3A encodes the histone 3 variant H3.3. Histones form part of the nucleosome complex around which DNA is coiled in the cell. H3F3A mutations affecting different hotspot residues, such as G35 (commonly referred to as G34 in the literature) and K28 (commonly known as K27), form different subgroups based on methylation and gene expression differences, the region of the brain affected, and clinical parameters (Sturm et al., 2012; 23079654). Recurrent mutations in the histone tail of H3F3A, at sites involved in critical post_translational modifications, have been reported at high frequency in pediatric and young adult brain tumors, including diffuse midline gliomas (Solomon et al., 2016; 26517431), diffuse hemispheric glioma (Fontebasso et al., 2013; 23417712), glioblastomas (Pandit et al., 2016; ISPNO Abstract HG_58)(Schwartzentruber et al., 2012; 22286061, Venneti et al., 2014; 25200322), aggressive pediatric gliomas (Wu et al., 2012; 22286216), pilocytic astrocytomas (Hochart et al., 2015; 25909089), gangliogliomas (Joyon et al., 2016; 27219822), glial and glioneuronal tumors (Nguyen et al., 2015; 25389051), as well as in low_grade gliomas undergoing transformation and secondary high_grade gliomas (Mistry et al., 2015; 25667294). These mutations were commonly found concurrently with mutations in TP53 or in ATRX and DAXX, which form a complex required for H3.3 recruitment to DNA, and were mutually exclusive with IDH1 mutations, which indirectly affect methylation of critical H3.3 residues (Schwartzentruber et al., 2012; 22286061). H3F3A K28M (also known as K27M) is a poor prognostic marker in glioma (NCCN CNS Cancers Guidelines, v2.2021). H3F3A G35 mutations are associated with disease onset during adolescence, whereas K28 mutations affect younger children and predict poorer IOS (Sturm et al., 2012; 23079654, Venneti et al., 2014; 25200322). H3F3A K28M mutation has also been identified in 58% of adult midline gliomas, and is associated with shorter OS for patients with brainstem gliomas but not for patients with thalamic gliomas (Feng et al., 2015; 26297251). Mutations of H3F3A or H3F3B, the other gene encoding histone H3.3, have also been detected in giant cell tumor of bone and chondroblastoma, with low mutation frequencies in other tumors of cartilage and bone (Behjati et al., 2013; 24162739, Kervarrec et al., 2017; 28059095, Righi et al., 2017; 28899740). H3F3B K37M (commonly known as K36M) has been identified in head and neck squamous cell carcinoma, specifically in tumors of the oral cavity (Papillon_Cavanagh et al., 2017; 28067913). Overexpression of H3F3A is associated with poor survival in lung adenocarcinomas, and is thought to promote cancer cell invasion (Park et al., 2016; 27694942). Prospective data from pooled clinical studies and preclinical evidence suggest that H3F3A K28M mutation predicts benefit from the investigational selective dopamine receptor D2 (DRD2) antagonist ONC201 (Chi et al., 2018; SNO abstract ACTR_34, Gardner et al., 2018; SNO abstract PDCT_06, Arrillaga_Romany et al., 2017; 29108308, Prabhu et al., 2018; 30559168), which is supported by increased expression of the ONC201 target DRD2 in H3F3A K28M_mutant versus wild_type gliomas (Chi et al, 2017; SNO abstract EXTH_42, Prabhu et al., 2018; 30559168). Among adult patients with recurrent H3F3A K28M_mutant gliomas, ONC201 achieved a DCR of 64% (7/11) and a 6_month PFS rate of 36% (5/14), with 3 patients experiencing complete and durable regressions of thalamic lesions (Chi et al., 2018; SNO abstract ACTR_34). Data from pooled ONC201 monotherapy trials showed that 31% (9/29) of patients with recurrent H3F3A K28M_mutated glioma remain progression free at 6.5 months median follow_up (Arrillaga et al., 2019; ASCO abstract 3005). Although other H3F3A mutations have been reported (Johnson et al., 2017; 28912153), it is unclear whether these therapeutic strategies would be relevant in gliomas with H3F3A mutations other than K28M. H3F3A K27M mutation is characteristic of diffuse midline glioma, H3 K27M_altered (NCCN CNS Cancers Guidelines, v2.2021)(Louis et al., 2021; 34185076, Pfister et al., 2022; 34921008).", "Include": "true", "ClinicalTrialNote": "On the basis of clinical and preclinical data, H3F3A K28M mutation may predict response to antagonists of dopamine receptors D2.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": {"nctId": "NCT03295396", "Include": "true"}}}}, "ReferenceLinks": null}, {"Name": "ATRX", "Include": "true", "Alterations": {"Alteration": {"Name": "H1363fs*12", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "H1363fs*12"}}, "Interpretation": "ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and W\u00f6hrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ERBB4", "Include": "true", "Alterations": {"Alteration": {"Name": "E542K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E542K"}}, "Interpretation": "ERBB4 (also known as HER4) encodes a member of the ErbB receptor tyrosine kinase family that plays a role in cell proliferation and apoptosis (Rudloff and Samuels, 2010; 20404484). Activating alterations are predicted to be oncogenic, and gain_of_function mutations have been identified throughout the gene (Kurppa et al., 2016; 26050618, Prickett et al., 2009; 19718025, Rudloff and Samuels, 2010; 20404484, Nakamura et al., 2016; 27207775). The variants N181S, V348L, P854Q, and T926M have demonstrated similar activity as wildtype ERBB4 in limited preclinical studies (Tvorogov et al., 2008; 19098003, Kurppa et al., 2016; 26050618). A single_nucleotide polymorphism in ERBB4 has been associated with increased risk of non_small cell lung cancer (NSCLC) in the Chinese Han population (Wang et al., 2021; 34106605). ERBB4 mutations have been identified in various solid tumors, including stomach (13%), salivary gland (11%, 2/18), esophageal (9%), lung (8_9%), endometrioid (6%), colorectal (5%), head and neck (5%), and gallbladder carcinomas (3.9%, 2/51), and melanoma (1.8%)(Prickett et al., 2009; 19718025, Kang et al., 2017; 27340278, Milewska et al., 2018; 29383036, Hu et al, 2021; 34620079, Li et al., 2014; 24997986, Dutton_Regester et al., 2012; 22383533). In hematological malignancies, ERBB4 mutations are rare, and have been reported at low frequency in diffuse large B_cell lymphoma (DLBCL)(2.2%_5.7%), chronic lymphocytic leukemia (CLL)(0.6_1.1%), and multiple myeloma (0.5%)(cBio_Chapuy et al., 2018; 29713087, cBio_Lohr et al., 2012; 22343534, cBio_Morin et al., 2013; 23699601, cBio_Puente et al., 2015; 26200345, cBio_Quesada et al., 2011; 22158541, cBio_Landau et al., 2015; 26466571, cBio_Lohr et al., 2014; 24434212). ERBB4 amplification has been predominantly detected in gastric tumors (67%)(Shi et al., 2012; 22606006). ERBB4 fusions have been identified infrequently in solid tumors and peripheral T_cell lymphoma, although evidence for ERBB4 fusions as driver alterations is generally limited (Schubert et al., 2021; ASCO Abstract 3091, Guenzi et al., 2021; 33816604, Nakaoku et al., 2014; 24727320, Guo et al., 2016; 26949921, Boddicker et al., 2016; 27297792). Expression of N_terminally truncated oncogenic ERBB4 variants has been reported in ALK fusion_negative anaplastic large cell lymphomas (Scarfo et al., 2016; 26463425). ERBB4 mutation correlates with poorer survival for patients with colorectal cancer (CRC)(Williams et al., 2015; 25916654). Increased ERBB4 expression has been associated with worse clinical outcomes for patients with CRC (Baiocchi et al., 2009; 19390858, Ljuslinder et al., 2009; 19443355), bone sarcoma (Merimsky et al., 2003; 12883746), esophageal squamous cell carcinoma (SCC)(Yu et al., 2018; 29729836), oral SCC (Silva et al., 2014; 24338375), metastatic Ewing sarcoma (Mendoza_Naranjo et al., 2013; 23681745), gastric cancer (Xu et al., 2018; 29620274), osteosarcoma (Huang et al., 2019; 31663373), or triple_negative breast cancer (Kim et al. 2016; 26907936). In contrast, high ERBB4 expression has been described as a positive prognostic factor in breast cancer (Witton et al., 2003; 12845624, Fuchs et al., 2006; 17201160, Wang et al., 2016; 27736797), ovarian cancer (Gilmour et al., 2001; 11280782), cervical carcinomas (Lee et al., 2005; 16157365), hormone_sensitive and castrate_resistant prostate cancer (Edwards et al., 2006; 16397033), and EGFR_negative intrahepatic cholangiocarcinoma (Yang et al., 2014; 24927194). The ERBB family kinase inhibitors afatinib and lapatinib, the EGFR inhibitors erlotinib and gefitinib, and the Bruton tyrosine kinase inhibitor ibrutinib have been shown to inhibit ERBB4 at clinically achievable concentrations (Solca et al., 2012; 22888144, Nam et al., 2011; 21306821, Davis et al., 2011; 22037378, Qiu et al., 2008; 18334220, Karaman et al., 2008; 18183025, Rauf et al., 2018; 29398709). However, whether these inhibitors would be clinically effective for patients with ERBB4 mutation is unclear. Retrospective analyses of the Phase 3 LUX_Lung 8 trial reported that patients with squamous non_small cell lung cancer (NSCLC) harboring mutations in ERBB family members exhibited long_term benefit following afatinib treatment compared with patients with ERBB_wildtype tumors; there was no difference for patients treated with erlotinib (Goss et al., 2018; 29902295, Goss et al., 2021; 34195574). A meta_analysis showed that patients with ERBB4_mutated NSCLC treated with immune checkpoint inhibitors exhibited longer PFS and OS compared with patients who had ERBB4_wildtype tumors (p=0.036 and p=0.0378)(Hu et al., 2021; 34620079).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "MCL1", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "MCL1 (myeloid cell leukemia 1) encodes a member of the BCL2 family that regulates apoptosis (Quinn et al., 2011; 21851287). Focal amplification of MCL1 has been reported in lung, breast, and other cancer types, and the survival of cells with MCL1 amplification is dependent on MCL1 expression (Beroukhim et al., 2010; 20164920). In non_small cell lung cancer (NSCLC), MCL1 amplification was significantly associated with increased MCL1 mRNA expression (Yin et al., 2016; 27264345). Although several MCL1 phosphorylation site mutations have been characterized (Thomas et al., 2010; 20540941), cancer_associated MCL1 mutations have not been reported (PubMed, Jan 2022). MCL1 amplification has been reported at the highest incidence in lung adenocarcinoma (16%)(Cancer Genome Atlas Research Network., 2014; 25079552), breast invasive carcinoma (15%)(Cancer Genome Atlas Network., 2012; 23000897), hepatocellular carcinoma (15%), and bladder urothelial carcinoma (13%)(Cancer Genome Atlas Research Network., 2014; 24476821) and at lower frequencies in other solid tumor types (cBioPortal, 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). MCL1 mutations have been reported in fewer than 1% of solid and hematologic cancers (COSMIC, 2022)(Tate et al., 2019; 30371878). In patients with NSCLC, MCL1 amplification was significantly associated with shorter overall survival (hazard ratio 1.39) (Yin et al., 2016; 27264345); high MCL1 protein expression alone was not prognostic in NSCLC (Schmidt et al., 2014; 25036876, Borner et al., 1999; 10070896, Wesarg et al., 2007; 17688235), whereas overexpression of both MCL1 and MYC was linked with poor survival (Allen et al., 2011; 21406400). High MCL1 expression has also been associated with poor prognosis in ovarian (Shigemasa et al., 2002; 12036450, Baekelandt et al., 2000; 11078490) and colorectal (Lee et al., 2014; 25628923) cancers. The prognostic significance of MCL1 expression in breast cancer is not clear (Ding et al., 2007; 17495324, O Driscoll et al., 2004; 15152946). There are no approved therapies to target MCL1 amplification, but MCL1 inhibitors including AMG 176, AMG 397, AZD5991, and S64315 (MIK665) are in early clinical development (Hird and Tron, 2019; 30790641, Caenepeel et al., 2018; 30254093, Tron et al., 2018; 30559424, Ramsey et al., 2018; 30185627). Limited preclinical data suggest that MCL1 expression alone may not be predictive of sensitivity to MCL1 inhibitors, but BH3 profiling may be a better predictor of MCL1 dependence (Caenepeel et al., 2018; 30254093, Kotschy et al., 2016; 27760111, Koch et al., 2019; 30498064, Ramsey et al., 2018; 30185627). Clinical and preclinical data indicate that increased MCL1 expression may be associated with resistance to BCL2_targeted agents such as venetoclax, navitoclax, or ABT_737 (Bose et al., 2017; 28140720, Roberts et al., 2012; 2218437, Konopleva et al., 2016; 27520294, Kumar et al., 2017; 29018077, Lin et al., 2016; 27283158, Suryani et al., 2014; 25013123, van Delft et al., 2006; 17097561, Konopleva et al., 2006; 17097560). In one study, amplification of the genomic locus containing MCL1 was acquired upon disease progression in patients with multiple myeloma treated with venetoclax (Neri et al., 2019; ASH Abstract 572). Combined inhibition of MCL1 and BCL2 may be more effective (Ramsey et al., 2018; 30185627, Moujalled et al., 2019; 30214012, Caenepeel et al., 2018; 30254093, Tron et al., 2018; 30559424, Leverson et al., 2015; 25590800). Indirect approaches using therapeutic agents that reduce MCL1 expression are also being investigated (Xiang et al., 2018; 30425521). Preclinical studies demonstrate that investigational cyclin_dependent kinase inhibitors targeting CDK9, such as dinaciclib, alvocidib, and voruciclib, suppress gene transcription, reduce MCL1 expression levels, and synergize with BCL2 inhibitors to induce apoptosis (Chen et al., 2016; 27469405, Jane et al., 2016; 26585571, Li et al., 2015; 25882699, Booher et al., 2014; 25289887, Zhou et al., 2018; 29241222, Bogenberger et al., 2017; 29291023, Chen et al., 2012; 22693249, Dey et al., 2017; 29269870). Preclinical studies in multiple types of cancer cells have also shown that the multikinase inhibitor sorafenib indirectly downregulates MCL1 and cooperates with BCL2_targeting agents (Arai et al., 2018; 30021909, Kiprianova et al., 2015; 26297434, Ricci et al., 2007; 17613437, Meng et al., 2007; 17698840), and a heavily pretreated patient with metastatic triple_negative breast cancer (TNBC) and MCL1 gene amplification responded to sorafenib in combination with several other therapies (Ali et al., 2016; 27293397). Preclinical studies of patient_derived tumor cells suggest that increased MCL1 levels may confer resistance to antitubulin therapies such as paclitaxel (Wertz et al., 2011; 21368834), and MCL1 amplification was reported to be more frequent in patients with TNBC and primary resistance to neoadjuvant chemotherapy (Balko et al., 2014; 24356096).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_High has been reported in 3_8% of adult or pediatric astrocytomas and was generally not associated with Lynch syndrome (Alonso et al., 2001; 11280776, Rodr\u00edguez_Hern\u00e1ndez et al., 2013; 24073290, Vladimirova et al., 2008; 18053027). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "PTPN11", "Include": "true", "Alterations": {"Alteration": {"Name": "T507K", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "T507K"}}, "Interpretation": "PTPN11 encodes the protein tyrosine_protein phosphatase non_receptor type 11, also known as SHP_2. PTPN11 plays a critical role in both embryonic development and cancer (Grossmann et al., 2010; 20399956). PTPN11 is also known to be somatically mutated in a variety of cancers, where both oncogenic and tumor suppressor roles for PTPN11 have been described (Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). The N_terminal SRC homology 2 (SH2) domain (aa 6_102) negatively regulates SHP_2 activity by binding to the active site of the SHP_2 protein tyrosine phosphatase (PTP) domain (aa 247_521)(Hof et al., 1998; 9791886). Alterations that disrupt this interaction or affect the specificity and structure of the SH2 and PTP domains, such as seen here, have been characterized as activating (Chan et al., 2007; 17053061, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Tartaglia et al., 2006; 16358218, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Bentires_Alj et al., 2004; 15604238, O Reilly et al., 2000; 10594032, Eminaga et al., 2008; 18378677, Martinelli et al., 2012; 22711529, Eminaga and Bennett., 2008; 18378677, Edwards et al., 2014; 24891296, Yu et al., 2014; 24935154, Martinelli et al., 2008; 18372317, LaRochelle et al., 2016; 27030275, LaRochelle et al., 2018; 30375388) and are predicted to be oncogenic (Mohi et al., 2005; 15710330, Bentires_Alj et al., 2004; 15604238, Tartaglia et al., 2006; 16358218, Schubbert et al., 2005; 15761018, Chan et al., 2005; 15644411, Tartaglia et al., 2003; 12717436, Wang et al., 2009; 19008228, Niihori et al., 2005; 15834506, Chan et al., 2009; 19179468, Xu et al., 2010; 20651068). In the Brain Lower Grade Glioma and Glioblastoma Multiforme TCGA datasets, PTPN11 mutations have been reported in fewer than 1% of cases (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). PTPN11 mutations in glioma subtypes have also been reported in the scientific literature, and recurrent activating PTPN11 mutations have been detected in pilocytic astrocytomas (Sturla et al., 2011; 21934682, Jones et al., 2013; 23817572, Schuettpelz et al., 2009; 19621452). PTPN11 mutations in glioblastoma have been associated with young patient age (Ferguson et al., 2016; 27579614), but their prognostic significance in gliomas in general have not been extensively studied (PubMed, Aug 2021). While both oncogenic and tumor suppressor roles for PTPN11 has been described, its role in glioblastoma tumorigenesis is likely to be oncogenic (Jones et al., 2013; 23817572, Tartaglia et al., 2003; 12717436, Bard_Chapeau et al., 2011; 21575863, Sturla et al., 2011; 21934682). SHP_2 has been reported to activate the RAS_MEK_ERK, PI3K_AKT_mTOR, and SRC kinase pathways (Liu et al., 2011; 21393858, Feng et al., 2012; 21996738, Wang et al., 2009; 19008228, Zhou and Agazie, 2008; 18421299). Based on a case study of a patient with histiocytic sarcoma harboring an activating PTPN11 mutation who experienced a PR to trametinib (Voruz et al., 2018; 29097496), as well as preclinical data (Tasian et al., 2019; 29884903, Krenz et al., 2005; 16166557, Nakamura et al., 2009; 19706403), PTPN11 activation may predict sensitivity to MEK inhibitors in histiocytic neoplasms. Germline mutations in PTPN11 have been found in the developmental disorder Noonan syndrome, which predisposes individuals to various cancers, including embryonal rhabdomyosarcoma, neuroblastoma, and juvenile myelomonocytic leukemia (Brasil et al., 2010; 20578946, Hasle, 2009; 20029231, Chen et al., 2006; 16518851, Tartaglia et al., 2006; 16358218, Pierpont et al., 2009; 19077116, Mathur et al., 2014; 24754368).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TET2", "Include": "true", "Alterations": {"Alteration": {"Name": "E1151*", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E1151*"}}, "Interpretation": "TET2 encodes a tumor suppressor involved in reversing DNA methylation marks, a process critical for proper gene regulation (Ito et al., 2010; 20639862, Guo et al., 2011; 21496894). Alterations such as seen here may disrupt TET2 function or expression (Iyer et al., 2009; 19411852, Ko et al., 2010; 21057493, Yang et al., 2013; 22391558, Hu et al., 2013; 24315485, Wang et al., 2015; 25601757). TET2 alterations have been reported at relatively low frequencies in solid tumors and are more prevalent in hematological malignancies (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Published data investigating the prognostic implications of TET2 alterations in solid tumors are limited (PubMed, Jan 2022). There are no targeted therapies available to address genomic alterations in TET2 in solid tumors. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "03", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "03"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Anaplastic astrocytoma harbors a median TMB of 1.8 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "FGFR1", "Alteration": "N546K", "Title": "Study of Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "FGFR1, CSF1R, VEGFRs, PD_1", "Locations": "Shanghai (China), Beijing (China)", "NCTID": "NCT04169672", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "GI_101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1, CTLA_4", "Locations": "Suwon_si (Korea, Republic of), Seoul (Korea, Republic of)", "NCTID": "NCT04977453", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "NCCH2006/MK010 Trial (FORTUNE Trial)", "StudyPhase": "PHASE 2", "Target": "FGFR1, FGFR2, FGFR3", "Locations": "Higashi_Ku, Fukuoka (Japan), Sakyo_ku, Kyoto (Japan), Chuo_ku, Tokyo (Japan), Aoba_ku, Sendai, Miyagi (Japan), Kita_Ku, Sapporo, Hokkaido (Japan)", "NCTID": "NCT04962867", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "Study of MK_4830 as Monotherapy and in Combination With Pembrolizumab (MK_3475) in Participants With Advanced Solid Tumors (MK_4830_001)", "StudyPhase": "PHASE 1", "Target": "ITL4, FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Seoul (Korea, Republic of), Petah Tikva (Israel), Ramat Gan (Israel), Tel Aviv (Israel), Haifa (Israel), Warszawa (Poland), Gdansk (Poland), Heraklion (Greece), Washington, Hospitalet de Llobregat (Spain)", "NCTID": "NCT03564691", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ_63723283, an Anti_Programmed Cell Death (PD)_1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers", "StudyPhase": "PHASE 1", "Target": "PD_1, FGFRs", "Locations": "Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT03547037", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor", "StudyPhase": "PHASE 1", "Target": "CBP, Beta_catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Osakasayama (Japan), Chuo_Ku (Japan), Kashiwa (Japan)", "NCTID": "NCT04008797", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "Infigratinib in Recurrent Glioblastoma Patients", "StudyPhase": "PHASE null", "Target": "FGFR3, FGFR1, FGFR2", "Locations": "Arizona", "NCTID": "NCT04424966", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "A Study of ICP_192 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFR2, FGFR1, FGFR3, FGFR4", "Locations": "Macquarie Park (Australia), Melbourne (Australia), Clayton (Australia), Frankston (Australia), Colorado, Minnesota, Arizona, Ohio, Florida", "NCTID": "NCT04565275", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "FGFR1", "Alteration": "N546K", "Title": "A Multi_Center, Open_Label Study of Sulfatinib(HMPL_012) in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "FGFR1, CSF1R, VEGFRs", "Locations": "Milano (Italy), California, Colorado, Texas, New York, Tennessee, Virginia, Florida", "NCTID": "NCT02549937", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR1.", "Include": "true"}, {"Gene": "H3F3A", "Alteration": "K28M", "Title": "ONC201 in Adults With Recurrent H3 K27M_mutant Glioma", "StudyPhase": "PHASE 2", "Target": "DRD2, CLLP, DRD3", "Locations": "California, Minnesota, New York, Pennsylvania, Texas, North Carolina", "NCTID": "NCT03295396", "Note": "On the basis of clinical and preclinical data, H3F3A K28M mutation may predict response to antagonists of dopamine receptors D2.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "1", "ReferenceId": "19224897", "FullCitation": "Lew ED, et al. Sci Signal (2009) pmid: 19224897", "Include": "true"}, {"number": "2", "ReferenceId": "14602678", "FullCitation": "Liu A, et al. Development (2003) pmid: 14602678", "Include": "true"}, {"number": "3", "ReferenceId": "12112473", "FullCitation": "Petiot A, et al. Dev. Dyn. (2002) pmid: 12112473", "Include": "true"}, {"number": "4", "ReferenceId": "10918587", "FullCitation": "Hart KC, et al. Oncogene (2000) pmid: 10918587", "Include": "true"}, {"number": "5", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "6", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "7", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "8", "ReferenceId": "27577993", "FullCitation": "Ryall S, et al. Acta Neuropathol Commun (2016) pmid: 27577993", "Include": "true"}, {"number": "9", "ReferenceId": "23817572", "FullCitation": "Jones DT, et al. Nat. Genet. (2013) pmid: 23817572", "Include": "true"}, {"number": "10", "ReferenceId": "16186508", "FullCitation": "Rand V, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 16186508", "Include": "true"}, {"number": "11", "ReferenceId": "23583981", "FullCitation": "Zhang J, et al. Nat. Genet. (2013) pmid: 23583981", "Include": "true"}, {"number": "12", "ReferenceId": "25609060", "FullCitation": "Di Stefano AL, et al. Clin. Cancer Res. (2015) pmid: 25609060", "Include": "true"}, {"number": "13", "ReferenceId": "26083571", "FullCitation": "Becker AP, et al. J. Neuropathol. Exp. Neurol. (2015) pmid: 26083571", "Include": "true"}, {"number": "14", "ReferenceId": "34580728", "FullCitation": "Ahrendsen JT, et al. J Neuropathol Exp Neurol (2021) pmid: 34580728", "Include": "true"}, {"number": "15", "ReferenceId": "33433639", "FullCitation": "Sch\u00fcller U, et al. Acta Neuropathol (2021) pmid: 33433639", "Include": "true"}, {"number": "16", "ReferenceId": "31340094", "FullCitation": "Loriot Y, et al. N. Engl. J. Med. (2019) pmid: 31340094", "Include": "true"}, {"number": "17", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "18", "ReferenceId": "28416604", "FullCitation": "Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604", "Include": "true"}, {"number": "19", "ReferenceId": "29848605", "FullCitation": "Pal SK, et al. Cancer Discov (2018) pmid: 29848605", "Include": "true"}, {"number": "20", "ReferenceId": "32208524", "FullCitation": "Pal SK, et al. Cancer (2020) pmid: 32208524", "Include": "true"}, {"number": "21", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "22", "ReferenceId": "34250399", "FullCitation": "Farouk Sait S, et al. JCO Precis Oncol (2021) pmid: 34250399", "Include": "true"}, {"number": "23", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "24", "ReferenceId": "32622884", "FullCitation": "Bahleda R, et al. Ann Oncol (2020) pmid: 32622884", "Include": "true"}, {"number": "25", "ReferenceId": "28972963", "FullCitation": "Papadopoulos KP, et al. Br. J. Cancer (2017) pmid: 28972963", "Include": "true"}, {"number": "26", "ReferenceId": "29223982", "FullCitation": "Cheng FT, et al. J Natl Compr Canc Netw (2017) pmid: 29223982", "Include": "true"}, {"number": "27", "ReferenceId": "26055304", "FullCitation": "Khodadoust MS, et al. Leukemia (2016) pmid: 26055304", "Include": "true"}, {"number": "28", "ReferenceId": "31434701", "FullCitation": "Tanasi I, et al. Blood (2019) pmid: 31434701", "Include": "true"}, {"number": "29", "ReferenceId": "29119847", "FullCitation": "Strati P, et al. Leuk. Lymphoma (2018) pmid: 29119847", "Include": "true"}, {"number": "30", "ReferenceId": "29765547", "FullCitation": "Slosberg ED, et al. Oncotarget (2018) pmid: 29765547", "Include": "true"}, {"number": "31", "ReferenceId": "34921008", "FullCitation": "Pfister SM, et al. Cancer Discov (2022) pmid: 34921008", "Include": "true"}, {"number": "32", "ReferenceId": "32289278", "FullCitation": "Ryall S, et al. Cancer Cell (2020) pmid: 32289278", "Include": "true"}, {"number": "33", "ReferenceId": "26810070", "FullCitation": "Qaddoumi I, et al. Acta Neuropathol. (2016) pmid: 26810070", "Include": "true"}, {"number": "34", "ReferenceId": "23079654", "FullCitation": "Sturm D, et al. Cancer Cell (2012) pmid: 23079654", "Include": "true"}, {"number": "35", "ReferenceId": "26517431", "FullCitation": "Solomon DA, et al. Brain Pathol. (2016) pmid: 26517431", "Include": "true"}, {"number": "36", "ReferenceId": "23417712", "FullCitation": "Fontebasso AM, et al. Acta Neuropathol (2013) pmid: 23417712", "Include": "true"}, {"number": "37", "ReferenceId": "22286061", "FullCitation": "Schwartzentruber J, et al. Nature (2012) pmid: 22286061", "Include": "true"}, {"number": "38", "ReferenceId": "25200322", "FullCitation": "Venneti S, et al. Acta Neuropathol. (2014) pmid: 25200322", "Include": "true"}, {"number": "39", "ReferenceId": "22286216", "FullCitation": "Wu G, et al. Nat. Genet. (2012) pmid: 22286216", "Include": "true"}, {"number": "40", "ReferenceId": "25909089", "FullCitation": "Hochart A, et al. Ann Clin Transl Neurol (2015) pmid: 25909089", "Include": "true"}, {"number": "41", "ReferenceId": "27219822", "FullCitation": "Joyon N, et al. Neuropathol. Appl. Neurobiol. (2017) pmid: 27219822", "Include": "true"}, {"number": "42", "ReferenceId": "25389051", "FullCitation": "Nguyen AT, et al. Neuropathol. Appl. Neurobiol. (2015) pmid: 25389051", "Include": "true"}, {"number": "43", "ReferenceId": "25667294", "FullCitation": "Mistry M, et al. J. Clin. Oncol. (2015) pmid: 25667294", "Include": "true"}, {"number": "44", "ReferenceId": "26297251", "FullCitation": "Feng J, et al. Hum. Pathol. (2015) pmid: 26297251", "Include": "true"}, {"number": "45", "ReferenceId": "24162739", "FullCitation": "Behjati S, et al. Nat. Genet. (2013) pmid: 24162739", "Include": "true"}, {"number": "46", "ReferenceId": "28059095", "FullCitation": "Kervarrec T, et al. Mod Pathol (2017) pmid: 28059095", "Include": "true"}, {"number": "47", "ReferenceId": "28899740", "FullCitation": "Righi A, et al. Hum Pathol (2017) pmid: 28899740", "Include": "true"}, {"number": "48", "ReferenceId": "28067913", "FullCitation": "Papillon_Cavanagh S, et al. Nat. Genet. (2017) pmid: 28067913", "Include": "true"}, {"number": "49", "ReferenceId": "27694942", "FullCitation": "Park SM, et al. Nat Commun (2016) pmid: 27694942", "Include": "true"}, {"number": "50", "ReferenceId": "29108308", "FullCitation": "Arrillaga_Romany I, et al. Oncotarget (2017) pmid: 29108308", "Include": "true"}, {"number": "51", "ReferenceId": "30559168", "FullCitation": "Prabhu VV, et al. Clin. Cancer Res. (2018) pmid: 30559168", "Include": "true"}, {"number": "52", "ReferenceId": "34185076", "FullCitation": "Louis DN, et al. Neuro Oncol (2021) pmid: 34185076", "Include": "true"}, {"number": "53", "ReferenceId": "20404484", "FullCitation": "Rudloff U, et al. Cell Cycle (2010) pmid: 20404484", "Include": "true"}, {"number": "54", "ReferenceId": "26050618", "FullCitation": "Kurppa KJ, et al. Oncogene (2016) pmid: 26050618", "Include": "true"}, {"number": "55", "ReferenceId": "19718025", "FullCitation": "Prickett TD, et al. Nat. Genet. (2009) pmid: 19718025", "Include": "true"}, {"number": "56", "ReferenceId": "27207775", "FullCitation": "Nakamura Y, et al. Mol. Cancer Ther. (2016) pmid: 27207775", "Include": "true"}, {"number": "57", "ReferenceId": "19098003", "FullCitation": "Tvorogov D, et al. J. Biol. Chem. (2009) pmid: 19098003", "Include": "true"}, {"number": "58", "ReferenceId": "34106605", "FullCitation": "Wang WP, et al. Medicine (Baltimore) (2021) pmid: 34106605", "Include": "true"}, {"number": "59", "ReferenceId": "27340278", "FullCitation": "Kang H, et al. Clin. Cancer Res. (2017) pmid: 27340278", "Include": "true"}, {"number": "60", "ReferenceId": "29383036", "FullCitation": "Milewska M, et al. Ther Adv Med Oncol (2018) pmid: 29383036", "Include": "true"}, {"number": "61", "ReferenceId": "34620079", "FullCitation": "Hu X, et al. Mol Med (2021) pmid: 34620079", "Include": "true"}, {"number": "62", "ReferenceId": "24997986", "FullCitation": "Li M, et al. Nat. Genet. (2014) pmid: 24997986", "Include": "true"}, {"number": "63", "ReferenceId": "22383533", "FullCitation": "Dutton_Regester K, et al. Mol. Cancer Ther. (2012) pmid: 22383533", "Include": "true"}, {"number": "64", "ReferenceId": "29713087", "FullCitation": "Chapuy B, et al. Nat. Med. (2018) pmid: 29713087", "Include": "true"}, {"number": "65", "ReferenceId": "22343534", "FullCitation": "Lohr JG, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22343534", "Include": "true"}, {"number": "66", "ReferenceId": "23699601", "FullCitation": "Morin RD, et al. Blood (2013) pmid: 23699601", "Include": "true"}, {"number": "67", "ReferenceId": "26200345", "FullCitation": "Puente XS, et al. Nature (2015) pmid: 26200345", "Include": "true"}, {"number": "68", "ReferenceId": "22158541", "FullCitation": "Quesada V, et al. Nat. Genet. (2011) pmid: 22158541", "Include": "true"}, {"number": "69", "ReferenceId": "26466571", "FullCitation": "Landau DA, et al. Nature (2015) pmid: 26466571", "Include": "true"}, {"number": "70", "ReferenceId": "24434212", "FullCitation": "Lohr JG, et al. Cancer Cell (2014) pmid: 24434212", "Include": "true"}, {"number": "71", "ReferenceId": "22606006", "FullCitation": "Shi J, et al. Int J Mol Sci (2012) pmid: 22606006", "Include": "true"}, {"number": "72", "ReferenceId": "33816604", "FullCitation": "Guenzi E, et al. ERJ Open Res (2021) pmid: 33816604", "Include": "true"}, {"number": "73", "ReferenceId": "24727320", "FullCitation": "Nakaoku T, et al. Clin. Cancer Res. (2014) pmid: 24727320", "Include": "true"}, {"number": "74", "ReferenceId": "26949921", "FullCitation": "Guo T, et al. Int J Cancer (2016) pmid: 26949921", "Include": "true"}, {"number": "75", "ReferenceId": "27297792", "FullCitation": "Boddicker RL, et al. Blood (2016) pmid: 27297792", "Include": "true"}, {"number": "76", "ReferenceId": "26463425", "FullCitation": "Scarf\u00f2 I, et al. Blood (2016) pmid: 26463425", "Include": "true"}, {"number": "77", "ReferenceId": "25916654", "FullCitation": "Williams CS, et al. Carcinogenesis (2015) pmid: 25916654", "Include": "true"}, {"number": "78", "ReferenceId": "19390858", "FullCitation": "Baiocchi G, et al. Int J Colorectal Dis (2009) pmid: 19390858", "Include": "true"}, {"number": "79", "ReferenceId": "19443355", "FullCitation": "Ljuslinder I, et al. Anticancer Res. (2009) pmid: 19443355", "Include": "true"}, {"number": "80", "ReferenceId": "12883746", "FullCitation": "Merimsky O, et al. Oncol. Rep. () pmid: 12883746", "Include": "true"}, {"number": "81", "ReferenceId": "29729836", "FullCitation": "Yu W, et al. Pathol. Res. Pract. (2018) pmid: 29729836", "Include": "true"}, {"number": "82", "ReferenceId": "24338375", "FullCitation": "Silva SD, et al. Clin. Exp. Metastasis (2014) pmid: 24338375", "Include": "true"}, {"number": "83", "ReferenceId": "23681745", "FullCitation": "Mendoza_Naranjo A, et al. EMBO Mol Med (2013) pmid: 23681745", "Include": "true"}, {"number": "84", "ReferenceId": "29620274", "FullCitation": "Xu J, et al. Oncol Rep (2018) pmid: 29620274", "Include": "true"}, {"number": "85", "ReferenceId": "31663373", "FullCitation": "Huang Z, et al. Scand J Clin Lab Invest (2019) pmid: 31663373", "Include": "true"}, {"number": "86", "ReferenceId": "12845624", "FullCitation": "Witton CJ, et al. J. Pathol. (2003) pmid: 12845624", "Include": "true"}, {"number": "87", "ReferenceId": "17201160", "FullCitation": "Fuchs IB, et al. Anticancer Res. () pmid: 17201160", "Include": "true"}, {"number": "88", "ReferenceId": "27736797", "FullCitation": "Wang J, et al. Oncotarget (2016) pmid: 27736797", "Include": "true"}, {"number": "89", "ReferenceId": "11280782", "FullCitation": "Gilmour LM, et al. Cancer Res. (2001) pmid: 11280782", "Include": "true"}, {"number": "90", "ReferenceId": "16157365", "FullCitation": "Lee CM, et al. Gynecol. Oncol. (2005) pmid: 16157365", "Include": "true"}, {"number": "91", "ReferenceId": "16397033", "FullCitation": "Edwards J, et al. Clin. Cancer Res. (2006) pmid: 16397033", "Include": "true"}, {"number": "92", "ReferenceId": "24927194", "FullCitation": "Yang X, et al. Oncol. Rep. (2014) pmid: 24927194", "Include": "true"}, {"number": "93", "ReferenceId": "22888144", "FullCitation": "Solca F, et al. J. Pharmacol. Exp. Ther. (2012) pmid: 22888144", "Include": "true"}, {"number": "94", "ReferenceId": "21306821", "FullCitation": "Nam HJ, et al. Cancer Lett. (2011) pmid: 21306821", "Include": "true"}, {"number": "95", "ReferenceId": "22037378", "FullCitation": "Davis MI, et al. Nat. Biotechnol. (2011) pmid: 22037378", "Include": "true"}, {"number": "96", "ReferenceId": "18334220", "FullCitation": "Qiu C, et al. Structure (2008) pmid: 18334220", "Include": "true"}, {"number": "97", "ReferenceId": "18183025", "FullCitation": "Karaman MW, et al. Nat. Biotechnol. (2008) pmid: 18183025", "Include": "true"}, {"number": "98", "ReferenceId": "29398709", "FullCitation": "Rauf F, et al. Oncogene (2018) pmid: 29398709", "Include": "true"}, {"number": "99", "ReferenceId": "29902295", "FullCitation": "Goss GD, et al. JAMA Oncol (2018) pmid: 29902295", "Include": "true"}, {"number": "100", "ReferenceId": "34195574", "FullCitation": "Goss GD, et al. EClinicalMedicine (2021) pmid: 34195574", "Include": "true"}, {"number": "101", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "102", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "103", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "104", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "105", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "106", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "107", "ReferenceId": "11280776", "FullCitation": "Alonso M, et al. Cancer Res. (2001) pmid: 11280776", "Include": "true"}, {"number": "108", "ReferenceId": "24073290", "FullCitation": "Rodr\u00edguez_Hern\u00e1ndez I, et al. PLoS ONE (2013) pmid: 24073290", "Include": "true"}, {"number": "109", "ReferenceId": "18053027", "FullCitation": "Vladimirova V, et al. Neuropathol. Appl. Neurobiol. (2008) pmid: 18053027", "Include": "true"}, {"number": "110", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "111", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "112", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "113", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "114", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "115", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "116", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "117", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "118", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "119", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "120", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "121", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "122", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "123", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "124", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "125", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "126", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "127", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "128", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "129", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "130", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "131", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "132", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "133", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "134", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "135", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "136", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "137", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "138", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "139", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "140", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "141", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "142", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "143", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "144", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "145", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "146", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "147", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "148", "ReferenceId": "21851287", "FullCitation": "Quinn BA, et al. Expert Opin Investig Drugs (2011) pmid: 21851287", "Include": "true"}, {"number": "149", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "150", "ReferenceId": "27264345", "FullCitation": "Yin J, et al. Cancer Med (2016) pmid: 27264345", "Include": "true"}, {"number": "151", "ReferenceId": "20540941", "FullCitation": "Thomas LW, et al. FEBS Lett. (2010) pmid: 20540941", "Include": "true"}, {"number": "152", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "153", "ReferenceId": "23000897", "FullCitation": "Nature (2012) pmid: 23000897", "Include": "true"}, {"number": "154", "ReferenceId": "24476821", "FullCitation": "Nature (2014) pmid: 24476821", "Include": "true"}, {"number": "155", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "156", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "157", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "158", "ReferenceId": "25036876", "FullCitation": "Schmidt LH, et al. J Thorac Oncol (2014) pmid: 25036876", "Include": "true"}, {"number": "159", "ReferenceId": "10070896", "FullCitation": "Borner MM, et al. Br. J. Cancer (1999) pmid: 10070896", "Include": "true"}, {"number": "160", "ReferenceId": "17688235", "FullCitation": "Wesarg E, et al. Int. J. Cancer (2007) pmid: 17688235", "Include": "true"}, {"number": "161", "ReferenceId": "21406400", "FullCitation": "Allen TD, et al. Cancer Res. (2011) pmid: 21406400", "Include": "true"}, {"number": "162", "ReferenceId": "12036450", "FullCitation": "Shigemasa K, et al. Jpn. J. Cancer Res. (2002) pmid: 12036450", "Include": "true"}, {"number": "163", "ReferenceId": "11078490", "FullCitation": "Baekelandt M, et al. J. Clin. Oncol. (2000) pmid: 11078490", "Include": "true"}, {"number": "164", "ReferenceId": "25628923", "FullCitation": "Lee WS, et al. Am J Cancer Res (2015) pmid: 25628923", "Include": "true"}, {"number": "165", "ReferenceId": "17495324", "FullCitation": "Ding Q, et al. Cancer Res. (2007) pmid: 17495324", "Include": "true"}, {"number": "166", "ReferenceId": "15152946", "FullCitation": "O Driscoll L, et al. Anticancer Res. () pmid: 15152946", "Include": "true"}, {"number": "167", "ReferenceId": "30790641", "FullCitation": "Hird AW, et al. Pharmacol. Ther. (2019) pmid: 30790641", "Include": "true"}, {"number": "168", "ReferenceId": "30254093", "FullCitation": "Caenepeel S, et al. Cancer Discov (2018) pmid: 30254093", "Include": "true"}, {"number": "169", "ReferenceId": "30559424", "FullCitation": "Tron AE, et al. Nat Commun (2018) pmid: 30559424", "Include": "true"}, {"number": "170", "ReferenceId": "30185627", "FullCitation": "Ramsey HE, et al. Cancer Discov (2018) pmid: 30185627", "Include": "true"}, {"number": "171", "ReferenceId": "27760111", "FullCitation": "Kotschy A, et al. Nature (2016) pmid: 27760111", "Include": "true"}, {"number": "172", "ReferenceId": "30498064", "FullCitation": "Koch R, et al. Blood (2019) pmid: 30498064", "Include": "true"}, {"number": "173", "ReferenceId": "28140720", "FullCitation": "Bose P, et al. Leuk. Lymphoma (2017) pmid: 28140720", "Include": "true"}, {"number": "174", "ReferenceId": "2218437", "FullCitation": "Stabell B, et al. Scand J Psychol (1990) pmid: 2218437", "Include": "true"}, {"number": "175", "ReferenceId": "27520294", "FullCitation": "Konopleva M, et al. Cancer Discov (2016) pmid: 27520294", "Include": "true"}, {"number": "176", "ReferenceId": "29018077", "FullCitation": "Kumar S, et al. Blood (2017) pmid: 29018077", "Include": "true"}, {"number": "177", "ReferenceId": "27283158", "FullCitation": "Lin KH, et al. Sci Rep (2016) pmid: 27283158", "Include": "true"}, {"number": "178", "ReferenceId": "25013123", "FullCitation": "Suryani S, et al. Clin. Cancer Res. (2014) pmid: 25013123", "Include": "true"}, {"number": "179", "ReferenceId": "17097561", "FullCitation": "van Delft MF, et al. Cancer Cell (2006) pmid: 17097561", "Include": "true"}, {"number": "180", "ReferenceId": "17097560", "FullCitation": "Konopleva M, et al. Cancer Cell (2006) pmid: 17097560", "Include": "true"}, {"number": "181", "ReferenceId": "30214012", "FullCitation": "Moujalled DM, et al. Leukemia (2019) pmid: 30214012", "Include": "true"}, {"number": "182", "ReferenceId": "25590800", "FullCitation": "Leverson JD, et al. Cell Death Dis (2015) pmid: 25590800", "Include": "true"}, {"number": "183", "ReferenceId": "30425521", "FullCitation": "Xiang W, et al. Onco Targets Ther (2018) pmid: 30425521", "Include": "true"}, {"number": "184", "ReferenceId": "27469405", "FullCitation": "Chen Y, et al. Br. J. Haematol. (2016) pmid: 27469405", "Include": "true"}, {"number": "185", "ReferenceId": "26585571", "FullCitation": "Jane EP, et al. J. Pharmacol. Exp. Ther. (2016) pmid: 26585571", "Include": "true"}, {"number": "186", "ReferenceId": "25882699", "FullCitation": "Li L, et al. Leukemia (2015) pmid: 25882699", "Include": "true"}, {"number": "187", "ReferenceId": "25289887", "FullCitation": "Booher RN, et al. PLoS ONE (2014) pmid: 25289887", "Include": "true"}, {"number": "188", "ReferenceId": "29241222", "FullCitation": "Zhou L, et al. Br. J. Cancer (2018) pmid: 29241222", "Include": "true"}, {"number": "189", "ReferenceId": "29291023", "FullCitation": "Bogenberger J, et al. Oncotarget (2017) pmid: 29291023", "Include": "true"}, {"number": "190", "ReferenceId": "22693249", "FullCitation": "Chen S, et al. Cancer Res. (2012) pmid: 22693249", "Include": "true"}, {"number": "191", "ReferenceId": "29269870", "FullCitation": "Dey J, et al. Sci Rep (2017) pmid: 29269870", "Include": "true"}, {"number": "192", "ReferenceId": "30021909", "FullCitation": "Arai S, et al. Clin. Cancer Res. (2018) pmid: 30021909", "Include": "true"}, {"number": "193", "ReferenceId": "26297434", "FullCitation": "Kiprianova I, et al. Neoplasia (2015) pmid: 26297434", "Include": "true"}, {"number": "194", "ReferenceId": "17613437", "FullCitation": "Ricci MS, et al. Cancer Cell (2007) pmid: 17613437", "Include": "true"}, {"number": "195", "ReferenceId": "17698840", "FullCitation": "Meng XW, et al. J. Biol. Chem. (2007) pmid: 17698840", "Include": "true"}, {"number": "196", "ReferenceId": "27293397", "FullCitation": "Ali SM, et al. Case Rep Oncol () pmid: 27293397", "Include": "true"}, {"number": "197", "ReferenceId": "21368834", "FullCitation": "Wertz IE, et al. Nature (2011) pmid: 21368834", "Include": "true"}, {"number": "198", "ReferenceId": "24356096", "FullCitation": "Balko JM, et al. Cancer Discov (2014) pmid: 24356096", "Include": "true"}, {"number": "199", "ReferenceId": "20399956", "FullCitation": "Grossmann KS, et al. Adv. Cancer Res. (2010) pmid: 20399956", "Include": "true"}, {"number": "200", "ReferenceId": "12717436", "FullCitation": "Tartaglia M, et al. Nat. Genet. (2003) pmid: 12717436", "Include": "true"}, {"number": "201", "ReferenceId": "21575863", "FullCitation": "Bard_Chapeau EA, et al. Cancer Cell (2011) pmid: 21575863", "Include": "true"}, {"number": "202", "ReferenceId": "21934682", "FullCitation": "Sturla LM, et al. Br. J. Cancer (2011) pmid: 21934682", "Include": "true"}, {"number": "203", "ReferenceId": "9791886", "FullCitation": "Sarkisian KA, et al. Vopr. Virusol. () pmid: 9791886", "Include": "true"}, {"number": "204", "ReferenceId": "17053061", "FullCitation": "Chan RJ, et al. Blood (2007) pmid: 17053061", "Include": "true"}, {"number": "205", "ReferenceId": "15644411", "FullCitation": "Chan RJ, et al. Blood (2005) pmid: 15644411", "Include": "true"}, {"number": "206", "ReferenceId": "16358218", "FullCitation": "Tartaglia M, et al. Am. J. Hum. Genet. (2006) pmid: 16358218", "Include": "true"}, {"number": "207", "ReferenceId": "19008228", "FullCitation": "Wang S, et al. J. Biol. Chem. (2009) pmid: 19008228", "Include": "true"}, {"number": "208", "ReferenceId": "15834506", "FullCitation": "Niihori T, et al. J. Hum. Genet. (2005) pmid: 15834506", "Include": "true"}, {"number": "209", "ReferenceId": "15604238", "FullCitation": "Bentires_Alj M, et al. Cancer Res. (2004) pmid: 15604238", "Include": "true"}, {"number": "210", "ReferenceId": "10594032", "FullCitation": "O Reilly AM, et al. Mol. Cell. Biol. (2000) pmid: 10594032", "Include": "true"}, {"number": "211", "ReferenceId": "18378677", "FullCitation": "Eminaga S, et al. J. Biol. Chem. (2008) pmid: 18378677", "Include": "true"}, {"number": "212", "ReferenceId": "22711529", "FullCitation": "Martinelli S, et al. J. Biol. Chem. (2012) pmid: 22711529", "Include": "true"}, {"number": "213", "ReferenceId": "24891296", "FullCitation": "Edwards JJ, et al. Am. J. Med. Genet. A (2014) pmid: 24891296", "Include": "true"}, {"number": "214", "ReferenceId": "24935154", "FullCitation": "Yu ZH, et al. Biochemistry (2014) pmid: 24935154", "Include": "true"}, {"number": "215", "ReferenceId": "18372317", "FullCitation": "Martinelli S, et al. Hum. Mol. Genet. (2008) pmid: 18372317", "Include": "true"}, {"number": "216", "ReferenceId": "27030275", "FullCitation": "LaRochelle JR, et al. Biochemistry (2016) pmid: 27030275", "Include": "true"}, {"number": "217", "ReferenceId": "30375388", "FullCitation": "LaRochelle JR, et al. Nat Commun (2018) pmid: 30375388", "Include": "true"}, {"number": "218", "ReferenceId": "15710330", "FullCitation": "Mohi MG, et al. Cancer Cell (2005) pmid: 15710330", "Include": "true"}, {"number": "219", "ReferenceId": "15761018", "FullCitation": "Schubbert S, et al. Blood (2005) pmid: 15761018", "Include": "true"}, {"number": "220", "ReferenceId": "19179468", "FullCitation": "Chan G, et al. Blood (2009) pmid: 19179468", "Include": "true"}, {"number": "221", "ReferenceId": "20651068", "FullCitation": "Xu D, et al. Blood (2010) pmid: 20651068", "Include": "true"}, {"number": "222", "ReferenceId": "19621452", "FullCitation": "Schuettpelz LG, et al. Pediatr Blood Cancer (2009) pmid: 19621452", "Include": "true"}, {"number": "223", "ReferenceId": "27579614", "FullCitation": "Ferguson SD, et al. Oncotarget (2016) pmid: 27579614", "Include": "true"}, {"number": "224", "ReferenceId": "21393858", "FullCitation": "Liu KW, et al. J. Clin. Invest. (2011) pmid: 21393858", "Include": "true"}, {"number": "225", "ReferenceId": "21996738", "FullCitation": "Feng H, et al. Oncogene (2012) pmid: 21996738", "Include": "true"}, {"number": "226", "ReferenceId": "18421299", "FullCitation": "Zhou XD, et al. Cell Death Differ. (2008) pmid: 18421299", "Include": "true"}, {"number": "227", "ReferenceId": "29097496", "FullCitation": "Voruz S, et al. Haematologica (2018) pmid: 29097496", "Include": "true"}, {"number": "228", "ReferenceId": "29884903", "FullCitation": "Tasian SK, et al. Leukemia (2019) pmid: 29884903", "Include": "true"}, {"number": "229", "ReferenceId": "16166557", "FullCitation": "Krenz M, et al. Circ. Res. (2005) pmid: 16166557", "Include": "true"}, {"number": "230", "ReferenceId": "19706403", "FullCitation": "Nakamura T, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19706403", "Include": "true"}, {"number": "231", "ReferenceId": "20578946", "FullCitation": "Brasil AS, et al. Genet Test Mol Biomarkers (2010) pmid: 20578946", "Include": "true"}, {"number": "232", "ReferenceId": "20029231", "FullCitation": "Horm. Res. (2009) pmid: 20029231", "Include": "true"}, {"number": "233", "ReferenceId": "16518851", "FullCitation": "Chen Y, et al. Genes Chromosomes Cancer (2006) pmid: 16518851", "Include": "true"}, {"number": "234", "ReferenceId": "19077116", "FullCitation": "Pierpont EI, et al. Genes Brain Behav. (2009) pmid: 19077116", "Include": "true"}, {"number": "235", "ReferenceId": "24754368", "FullCitation": "Mathur D, et al. Fetal Pediatr Pathol (2014) pmid: 24754368", "Include": "true"}, {"number": "236", "ReferenceId": "20639862", "FullCitation": "Ito S, et al. Nature (2010) pmid: 20639862", "Include": "true"}, {"number": "237", "ReferenceId": "21496894", "FullCitation": "Guo JU, et al. Cell (2011) pmid: 21496894", "Include": "true"}, {"number": "238", "ReferenceId": "19411852", "FullCitation": "Iyer LM, et al. Cell Cycle (2009) pmid: 19411852", "Include": "true"}, {"number": "239", "ReferenceId": "21057493", "FullCitation": "Ko M, et al. Nature (2010) pmid: 21057493", "Include": "true"}, {"number": "240", "ReferenceId": "22391558", "FullCitation": "Yang H, et al. Oncogene (2013) pmid: 22391558", "Include": "true"}, {"number": "241", "ReferenceId": "24315485", "FullCitation": "Hu L, et al. Cell (2013) pmid: 24315485", "Include": "true"}, {"number": "242", "ReferenceId": "25601757", "FullCitation": "Wang Y, et al. Mol. Cell (2015) pmid: 25601757", "Include": "true"}, {"number": "243", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "244", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "245", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "246", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "247", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "248", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "249", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "250", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "251", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "252", "ReferenceId": "23916100", "FullCitation": "Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100", "Include": "true"}, {"number": "253", "ReferenceId": "23249563", "FullCitation": "Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563", "Include": "true"}, {"number": "254", "ReferenceId": "22829774", "FullCitation": "Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774", "Include": "true"}, {"number": "255", "ReferenceId": "23185534", "FullCitation": "Bower K, et al. PLoS ONE (2012) pmid: 23185534", "Include": "true"}, {"number": "256", "ReferenceId": "21719641", "FullCitation": "Heaphy CM, et al. Science (2011) pmid: 21719641", "Include": "true"}, {"number": "257", "ReferenceId": "25229770", "FullCitation": "Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770", "Include": "true"}, {"number": "258", "ReferenceId": "17296936", "FullCitation": "Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936", "Include": "true"}, {"number": "259", "ReferenceId": "14729260", "FullCitation": "Garrick D, et al. Gene (2004) pmid: 14729260", "Include": "true"}, {"number": "260", "ReferenceId": "21666677", "FullCitation": "Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677", "Include": "true"}, {"number": "261", "ReferenceId": "25593184", "FullCitation": "Flynn RL, et al. Science (2015) pmid: 25593184", "Include": "true"}, {"number": "262", "ReferenceId": "7697714", "FullCitation": "Gibbons RJ, et al. Cell (1995) pmid: 7697714", "Include": "true"}, {"number": "263", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "264", "ReferenceId": "25608029", "FullCitation": "Fishbein L, et al. Nat Commun (2015) pmid: 25608029", "Include": "true"}, {"number": "265", "ReferenceId": "22416102", "FullCitation": "Cheung NK, et al. JAMA (2012) pmid: 22416102", "Include": "true"}, {"number": "266", "ReferenceId": "22367537", "FullCitation": "Molenaar JJ, et al. Nature (2012) pmid: 22367537", "Include": "true"}, {"number": "267", "ReferenceId": "23334666", "FullCitation": "Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666", "Include": "true"}, {"number": "268", "ReferenceId": "23702928", "FullCitation": "Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928", "Include": "true"}, {"number": "269", "ReferenceId": "24148618", "FullCitation": "Marinoni I, et al. Gastroenterology (2014) pmid: 24148618", "Include": "true"}, {"number": "270", "ReferenceId": "24468746", "FullCitation": "Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746", "Include": "true"}, {"number": "271", "ReferenceId": "26936505", "FullCitation": "Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505", "Include": "true"}, {"number": "272", "ReferenceId": "23104868", "FullCitation": "Kannan K, et al. Oncotarget (2012) pmid: 23104868", "Include": "true"}, {"number": "273", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "274", "ReferenceId": "25427834", "FullCitation": "Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834", "Include": "true"}, {"number": "275", "ReferenceId": "25143301", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301", "Include": "true"}, {"number": "276", "ReferenceId": "31551363", "FullCitation": "Liang J, et al. Cancer Res (2020) pmid: 31551363", "Include": "true"}, {"number": "277", "ReferenceId": "34118569", "FullCitation": "Garbarino J, et al. Transl Oncol (2021) pmid: 34118569", "Include": "true"}, {"number": "278", "ReferenceId": "32846370", "FullCitation": "George SL, et al. EBioMedicine (2020) pmid: 32846370", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_04_19 23:54:36", "OpName": "Donna Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Donna Ferguson, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "759x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "3 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain anaplastic astrocytoma", "flowcell_analysis": "2000021284", "gender": "female", "pathology_diagnosis": "Anaplastic Astrocytoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.10.2", "purity_assessment": "80.2", "specimen": "ORD_1341410_01*US1289010.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1341410_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "777.1", "name": "SQ_US1289010.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5363", "cds_effect": "3451G>T", "depth": "662", "equivocal": "false", "functional_effect": "nonsense", "gene": "TET2", "percent_reads": "53.63", "position": "chr4:106158550", "protein_effect": "E1151*", "status": "likely", "strand": "+", "transcript": "NM_017628", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.4019", "cds_effect": "83A>T", "depth": "520", "equivocal": "false", "functional_effect": "missense", "gene": "H3F3A", "percent_reads": "40.19", "position": "chr1:226252135", "protein_effect": "K28M", "status": "known", "strand": "+", "transcript": "NM_002107", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.5307", "cds_effect": "2386A>T", "depth": "897", "equivocal": "false", "functional_effect": "missense", "gene": "SPEN", "percent_reads": "53.07", "position": "chr1:16255121", "protein_effect": "T796S", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.0863", "cds_effect": "334C>T", "depth": "371", "equivocal": "false", "functional_effect": "missense", "gene": "PDGFRA", "percent_reads": "8.63", "position": "chr4:55127546", "protein_effect": "L112F", "status": "unknown", "strand": "+", "transcript": "NM_006206", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.2405", "cds_effect": "659G>A", "depth": "1048", "equivocal": "false", "functional_effect": "missense", "gene": "NTRK1", "percent_reads": "24.05", "position": "chr1:156838381", "protein_effect": "R220Q", "status": "unknown", "strand": "+", "transcript": "NM_002529", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.4951", "cds_effect": "2215G>A", "depth": "515", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "49.51", "position": "chr19:15296149", "protein_effect": "E739K", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.2316", "cds_effect": "1520C>A", "depth": "1058", "equivocal": "false", "functional_effect": "missense", "gene": "PTPN11", "percent_reads": "23.16", "position": "chr12:112926900", "protein_effect": "T507K", "status": "known", "strand": "+", "transcript": "NM_002834", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.4361", "cds_effect": "4089delT", "depth": "798", "equivocal": "false", "functional_effect": "frameshift", "gene": "ATRX", "percent_reads": "43.61", "position": "chrX:76918901", "protein_effect": "H1363fs*12", "status": "likely", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.4805", "cds_effect": "649C>T", "depth": "693", "equivocal": "false", "functional_effect": "missense", "gene": "MLH1", "percent_reads": "48.05", "position": "chr3:37053562", "protein_effect": "R217C", "status": "unknown", "strand": "+", "transcript": "NM_000249", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.6481", "cds_effect": "1738G>A", "depth": "1040", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR3", "percent_reads": "64.81", "position": "chr4:1807569", "protein_effect": "D580N", "status": "unknown", "strand": "+", "transcript": "NM_000142", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.5062", "cds_effect": "1624G>A", "depth": "644", "equivocal": "false", "functional_effect": "missense", "gene": "ERBB4", "percent_reads": "50.62", "position": "chr2:212537981", "protein_effect": "E542K", "status": "known", "strand": "_", "transcript": "NM_005235", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.4339", "cds_effect": "5230C>T", "depth": "590", "equivocal": "false", "functional_effect": "missense", "gene": "MTOR", "percent_reads": "43.39", "position": "chr1:11194424", "protein_effect": "H1744Y", "status": "unknown", "strand": "_", "transcript": "NM_004958", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}, {"allele_fraction": "0.2977", "cds_effect": "1638C>A", "depth": "682", "equivocal": "false", "functional_effect": "missense", "gene": "FGFR1", "percent_reads": "29.77", "position": "chr8:38274849", "protein_effect": "N546K", "status": "known", "strand": "_", "transcript": "NM_023110", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": {"copy_number": "6", "equivocal": "true", "gene": "MCL1", "number_of_exons": "5 of 5", "position": "chr1:150511135_150600810", "ratio": "2.68", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1289010.01_1"}}}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "2.52", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}